WO2023117164A1 - Verfahren, vorrichtung und system zum ermitteln eines gesundheitszustands eines patienten - Google Patents
Verfahren, vorrichtung und system zum ermitteln eines gesundheitszustands eines patienten Download PDFInfo
- Publication number
- WO2023117164A1 WO2023117164A1 PCT/EP2022/076936 EP2022076936W WO2023117164A1 WO 2023117164 A1 WO2023117164 A1 WO 2023117164A1 EP 2022076936 W EP2022076936 W EP 2022076936W WO 2023117164 A1 WO2023117164 A1 WO 2023117164A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- glucose
- model
- state
- insulin
- Prior art date
Links
- 230000036541 health Effects 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 33
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 111
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 105
- 239000008103 glucose Substances 0.000 claims abstract description 105
- 229940125396 insulin Drugs 0.000 claims abstract description 60
- 102000004877 Insulin Human genes 0.000 claims abstract description 51
- 108090001061 Insulin Proteins 0.000 claims abstract description 51
- 230000035945 sensitivity Effects 0.000 claims abstract description 34
- 238000005259 measurement Methods 0.000 claims abstract description 25
- 230000004190 glucose uptake Effects 0.000 claims abstract description 11
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 8
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims abstract description 8
- 239000000859 incretin Substances 0.000 claims abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 34
- 230000006870 function Effects 0.000 claims description 19
- 238000013459 approach Methods 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- 238000004590 computer program Methods 0.000 claims description 7
- 230000033001 locomotion Effects 0.000 claims description 7
- 238000004891 communication Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 230000035764 nutrition Effects 0.000 claims description 4
- 238000013135 deep learning Methods 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 9
- 230000013632 homeostatic process Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 8
- 230000006978 adaptation Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 241001521293 Python Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000011511 automated evaluation Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7239—Details of waveform analysis using differentiation including higher order derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
Definitions
- the present invention relates to a device for determining a patient's state of health.
- the present invention further relates to a system and a method for determining a patient's state of health.
- the present invention relates to a computer program product.
- Diabetes mellitus colloquially diabetes or diabetes
- DM refers to a group of heterogeneous diseases, in particular metabolic disorders of carbohydrates, which include, among other things, disturbed glucose and insulin homeostasis and are associated with the common feature of chronic hyperglycemia ("hyperglycemia").
- the metabolic disorders are based, for example, on a disorder/dysfunction/resistance or deficiency in the glucose and insulin homeostasis (according to the underlying etiological form of diabetes) in a patient and can lead to chronic hyperglycemia if not treated or treated inadequately.
- DM diabetic foot syndrome or coronary artery disease
- IGT impaired glucose tolerance
- the object of the present invention is to enable precise modeling of a condition, in particular a state of health, of a patient.
- a state of health should also be made precisely and accurately ascertainable for different patients.
- the present invention relates in a first aspect to a device for determining a patient's state of health, having: an input interface for receiving a glucose measurement value with information about a glucose level of the patient and a glucose intake input value with information about a glucose intake of the patient; an estimation unit for determining the patient's state of health based on the received values and a predefined state model which maps the patient's state of health by means of a state vector and using a plurality of model parameters, the state vector comprising a glucose model value with information on the patient's glucose level; a comparison unit for determining a deviation between the glucose measurement value and the glucose model value; and an individualization unit for updating at least one model parameter individually for the patient based on the determined deviation.
- the present invention relates to a system for determining a patient's state of health, with a device as defined above and with a continuously measuring glucose sensor, (rt) CGM, and/or real-time flash glucose monitoring, (rt) -FGM, for taking a glucose reading with information about a patient's glucose level.
- aspects of the invention relate to a method designed according to the device and a computer program product with program code for carrying out the steps of the method when the program code is executed on a computer.
- one aspect of the invention relates to a storage medium on which a computer program is stored which, when executed on a computer, causes the method described herein to be carried out.
- a measured glucose value on the one hand and an input glucose value on the other is received in this respect.
- the glucose reading reflects the patient's current glucose level.
- a measured value recorded shortly beforehand by means of a corresponding measuring system or also provided in real time can be received in this respect.
- the glucose intake input value describes in particular an oral or intravenous glucose intake by the patient.
- the glucose input value can be recorded by means of a sensor, for example, or it can also be provided by the patient via an interface.
- a state of health of the patient is determined in the estimation unit based on the two received values.
- This state of health is described by means of a state vector, this state vector containing a number of state variables or states which, viewed together or individually, allow a statement to be made regarding the current state of health of the patient.
- the state model used is preferably time-discrete and the state vector is transferred from one point in time to a subsequent point in time by means of a predetermined function, possibly taking system inputs into account.
- the function is based on predefined and modifiable model parameters or includes such model parameters.
- the state vector provided according to the invention includes a glucose model value that indicates the patient's glucose level.
- a deviation between the glucose measurement value that was received and the glucose model value that was estimated as part of the state vector is determined in the comparison unit. Based on the deviation between the two values, one of the model parameters is updated on a patient-specific basis in the individualization unit. In other words, it is therefore proposed that at least one model parameter (which is not part of the state vector) is determined and updated online on the basis of a glucose measurement. In a model of a patient's glucose-insulin homeostasis, a model parameter is estimated.
- an individualization of a model of the patient's state of health can be achieved, which creates an improved prediction and thus an improved possibility for the patient to exert influence.
- the patient-specific adaptation or updating of the model parameter proposed according to the invention can provide the patient with an exact model of his state of health (also referred to as a digital twin). Based on this model, for example, individualized therapy suggestions or also individualized recommendations for action can then be determined in an automated manner and made available to the patient or the practitioner. Overall, there is an improved therapy option and quality of life for patients and a reduction in diabetes-associated co-morbidities and mortality.
- the status vector includes an insulin model value with information about the patient's insulin level.
- the multiple model parameters include a sensitivity parameter that reflects a patient's glucose and/or insulin sensitivity.
- the individualization unit is designed to update the sensitivity parameter.
- the approach according to the invention can be used in the DM environment.
- the state vector includes an insulin model value and the model is based on a model parameter that depicts the patient's glucose and/or insulin sensitivity. This sensitivity often varies from patient to patient. An adaptation of the state model to a patient results from an individualization of this model parameter. The possibility of forecasting using the state estimation proposed according to the invention is improved.
- the multiple model parameters include an incretin effect sensitivity parameter that maps a sensitivity of the patient's insulin level to glucose uptake.
- the individualization unit is designed to update the incretin effect sensitivity parameter.
- a further individualization can lie in an adaptation of a patient-specific incretin sensitivity of the patient.
- a sensitivity of the insulin level to a glucose uptake is mapped.
- Such a sensitivity can differ, for example, due to the patient's body weight or also due to their metabolic properties.
- the individualization unit is designed to update the model parameters based on a predefined cost function.
- a cost function it is possible to use a cost function to be able to make a selection when updating the model parameters.
- the cost function can be used, for example, to prioritize various adjustment options.
- the individualization unit is designed to determine a gradient with regard to the model parameters and to update the model parameters in a gradient method.
- a gradient method it is possible for a gradient method to be used, in which an update is carried out, for example, in the direction of a steepest descent (or ascent, depending on the definition of the sign).
- a gradient method is a method for solving optimization problems. In particular, an optimization should be carried out such that the best possible mapping of the real glucose measurement values and the estimated glucose model value is achieved by adapting the model parameters. The result is an individual adaptation of the modeling to a patient.
- the estimation unit is designed to update the state vector based on a previous state vector and based on a further predefined cost function and a further gradient method. It is possible that a gradient method is also used when updating the state vector. To this extent, a predetermined cost function is also used when updating the state vector.
- the predefined state model is a non-linear differential equation model.
- the predefined state model can be a non-linear differential equation model of order 9 or higher.
- the use of a non-linear differential equation model enables the state transitions and the states to be mapped with high precision, enabling accurate prediction. The result is a high level of precision when mapping the patient's state of health.
- the input interface is designed to receive the measured glucose value from a continuously measuring glucose sensor, (rt-)CGM, and/or a real-time flash glucose monitoring, (rt-)FGM.
- the input interface can be designed to receive the measured glucose value via a wireless communication link.
- the device according to the invention can then be implemented in the form of a smartphone or in the form of a smartphone app in order to be able to further process the corresponding sensor data.
- Communication via the Internet (cloud-based) is also conceivable.
- the device according to the invention is easy to use.
- the input interface is designed to receive an additional input value that includes information about nutrition, a state of movement, sleep, medication and/or a previous or concomitant illness of the patient.
- additional input value that includes information about nutrition, a state of movement, sleep, medication and/or a previous or concomitant illness of the patient.
- lifestyle parameters can be received as additional information, which can then be taken into account when determining the patient's state of health.
- Such additional input values often enable a further improvement in the accuracy in the prediction of the state of health of the person.
- the multiple model parameters include at least one additional sensitivity parameter that maps a patient's sensitivity to nutrition, a state of movement, sleep, medication and/or a previous or concomitant disease.
- the individualization unit is designed to update the additional sensitivity parameter.
- the various individual lifestyle parameters are taken into account in order to be able to map the patient's sensitivity to the various parameters. Different patients react differently to, for example, lack of sleep or changes in diet. These phenomena can be mapped by considering the additional input values or by using an additional sensitivity parameter. A further improved accuracy results.
- the device according to the invention comprises a dosing unit for determining a medication dosage as part of a diabetes therapy based on the status vector.
- the dosing unit is preferably designed to determine the medication dosage based on a model predictive control approach (MPC), a proportional-integral-differential controller (PID controller), a fuzzy controller and/or a deep learning approach.
- MPC model predictive control
- PID controller proportional-integral-differential controller
- a fuzzy controller a fuzzy controller
- a deep learning approach based on the determined state, an automated determination of a medication dosage can take place.
- an insulin dosage can be suggested.
- PID controllers, fuzzy controllers, model predictive control (MPC) or deep learning approaches can be used as control algorithms.
- the dosing unit to be designed to control an insulin pump, a smart pen or other devices for administering insulin.
- the input interface is designed to receive an insulin input value with information about the patient's current insulin dosage.
- the dosing unit is designed to determine a new insulin dose based on the status vector and the insulin input value. By additionally considering the patient's insulin dosage, a suggestion for a new insulin dosage can be determined for diabetics. The result is a further reduced susceptibility to errors.
- health-endangering situations and co-morbidities as well as inpatient admissions can be avoided.
- a state of health of a patient is understood here to mean, in particular, a representation of a state using different variables (which can also be referred to as parameters), which are combined in a state vector.
- Model parameters can be values that map the sensitivities of a patient to specific inputs.
- the state model maps a state to a state at a subsequent point in time using this function, taking into account received input values.
- a patient-specific update is understood here to mean a change in one of the model parameters, by means of which this model parameter is adapted to a property of an individual.
- FIG. 1 shows a schematic representation of a system according to the invention for determining a state of health of a patient
- FIG. 2 shows a schematic overview of a determination of states and parameters of a glucose-insulin model according to an embodiment of the approach of the present invention
- FIG. 3 shows a schematic representation of a device according to the invention
- FIGS. 4 and 5 show a schematic representation of an embodiment of the algorithm proposed according to the invention for the parallel tracking of parameters and states
- FIG. 6 shows a schematic representation of the method according to the invention for determining a state of health of a patient.
- the system 10 includes a device 12 for determining the state of health and a continuously measuring glucose sensor 14 ((rt)CGM and/or (rt)FGM sensor).
- the device 12 is in the form of a smartphone, which is in communication with the continuously measuring glucose sensor 14 attached by means of a bracelet or by means of an adhesive point via a Bluetooth connection and receives a glucose measurement value from it.
- the system 10 can also include, for example, an (optional) insulin pump 15 that can be controlled directly, for example also via a Bluetooth connection from the smartphone or via the Internet in a cloud-based or other approach.
- the approach according to the invention aims in particular at individualized diabetes therapy.
- measurements from (rt-)CGM and/or (rt-)FGM sensors have already been processed in models to model the glucose-insulin homeostasis of a diabetic patient.
- model states and parameters are to be continuously adjusted, which enable individual predictions and diagnoses in order to facilitate diabetes self-management by a diabetic patient.
- a direct control for drug dosing in particular an insulin pump, is optionally possible (closed-loop control).
- the system proposed according to the invention and the device proposed according to the invention are aimed at extensive automation in the sense of controlled operation of an insulin pump ("closed-loop” or “artificial pancreas”), in which a An insulin pump is activated.
- a device 12 according to the invention for determining a state of health of a patient is shown schematically in FIG.
- the device comprises an input interface 16, an estimation unit 18, a comparison unit 20 and an individualization unit 22.
- the device 12 also comprises an (optional) dosing unit 24.
- the units and interfaces can be partially or completely in software and/or in be implemented hardware.
- the units can be designed as processors, processor modules or also as software for a processor.
- the device 12 can in particular be designed in the form of a smartphone or another mobile device or as software or an app for a smartphone or a mobile device.
- parts of the device are made available as functionalities of a central server via the Internet (cloud-based).
- a patient can use a smartphone app to communicate with a server that is designed to make the functions of the above-mentioned units available in full or in part.
- a server that is designed to make the functions of the above-mentioned units available in full or in part.
- other components such as a CGM/FGM or an insulin pump or other components that are also Internet-enabled are included.
- the communication between different components of a system according to the invention can then take place via the Internet.
- a measured glucose value and, on the other hand, an input glucose uptake value are received via the input interface 16 .
- the glucose reading can be received directly from a corresponding (rt)CGM and/or (rt)FGM sensor, for example via a Bluetooth connection.
- the glucose reading shows in particular a current glucose level of the patient.
- the glucose uptake input value can be based, for example, on an input from the patient or on a measurement by a corresponding sensor and indicates a glucose uptake by the patient.
- the glucose intake input value can be used to indicate the amount of glucose the patient has consumed in a previous, predefined period of time.
- additional parameters can be received.
- lifestyle parameters can be received, for example parameters that include information about nutrition, a state of movement, sleep, medication and/or a previous or concomitant illness of the patient as additional input values.
- additional input values can also be taken into account in the further modeling of the patient's state of health.
- the format of a corresponding additional input value can be chosen individually.
- the values can be specified on a predefined scale. It is also conceivable that an assignment is made using a corresponding table, so that, for example, a movement or a movement state of a patient is classified into categories (e.g. no sport, sport once or twice a week, sport three to four times a week, more than five times a week sports etc.).
- a state of health of the patient is determined in the estimation unit 18 based on the received values.
- a predefined status model is used for this purpose, in which the patient's state of health is depicted by means of a status vector.
- the estimation unit can pass on the state of health or the state vector to a corresponding display device, for example. It is also conceivable that the estimation unit 18 is in contact via a mobile communication link, for example, with a doctor who evaluates the currently estimated state of health of the patient and, based on this, can make therapy recommendations, for example. In this respect, the estimation unit 18 forms a type of digital simulation (digital twin) of the patient.
- the patient, but also other interested parties can gain an insight into the current state of health of the patient. In particular, it is possible for an individual medication dosage to be determined directly as part of a diabetes therapy based on the status vector.
- the estimation unit 18 can use a predefined cost function and a gradient method to update the state vector. This optimizes a mathematical model, which in turn is used to update the state vector from one journal to the next. Different models can be used for this.
- the predefined state model in the estimation unit 18 can in particular be a non-linear differential equation model, in particular of order 9 or higher. This enables a reliable and accurate estimation of the state transition.
- a state vector is used in the estimation unit 18, which also includes a glucose model value.
- This glucose model value emulates the patient's glucose level and as such includes information about the patient's glucose level.
- a predefined scale can be used for this. For example, specifying a percentage is conceivable.
- a deviation between the measured glucose value and the glucose model value is now determined.
- the deviation can be determined in particular in the form of an absolute difference.
- at least one model parameter is updated in the individualization unit 20 . It allows a model parameter to represent a sensitivity parameter that reflects a patient's glucose and/or insulin sensitivity.
- the state vector can include an insulin model value that indicates the patient's insulin level.
- the model parameters can include a sensitivity parameter that depicts the patient's glucose and/or insulin sensitivity. Provision can then be made for the individualization unit 22 to be designed to adapt this sensitivity parameter and thereby achieve a patient-specific adaptation of the model. Each patient has an individual sensitivity to glucose or insulin administration.
- This individual sensitivity can be mapped to the extent that improved modeling results. It is also possible for an incretin effect sensitivity parameter to be used, which maps a sensitivity of the patient's insulin level to glucose uptake. It is then possible for the individualization unit 22 to update this incretin effect sensitivity parameter in order to thereby achieve a patient-specific adaptation of the model.
- the customization unit 22 can also use a predefined cost function. In particular, a gradient method can be used to update the model parameters.
- a drug dosing can be determined directly based on the state vector.
- medication is administered directly on this basis.
- an insulin dosage can be determined and an insulin pump can be controlled directly.
- AID Automated Insulin Delivery
- the algorithm proposed here for mapping the state of health of a patient using a state model preferably works in discrete journals k.
- the time step size in particular determined by the rate at which glucose is measured.
- (rt-)CGM and/or (rt-)FGM sensors typically output a new measured value yk every 1-5 minutes, and the algorithm is then run through once to update states X and model parameters 0k.
- the time-varying signals of the (state) model are referred to as states x/ ⁇ , such as the glucose or insulin concentration in the blood or in the tissue.
- states x/ ⁇ such as the glucose or insulin concentration in the blood or in the tissue.
- the states are summarized in the state vector.
- the update occurs through two mechanisms: In the first step, all states are taken into account in a model of glucose-insulin homeostasis. It is therefore possible to update them by simulating the model. For example, if it is known that food is currently being consumed (by the input glucose intake), the model will predict an increase in blood glucose. In the second step, the model output is compared with the current measurement. If there is a deviation, the states are corrected. For this purpose, this deviation is evaluated in the algorithm using a cost function Jk, for which the gradient k is determined with regard to the states Xk. Finally, this gradient can be used in a gradient method to correct the state predicted on the basis of the model.
- model parameters 0k The constants of the state model that do not change over time are referred to as model parameters 0k.
- a model of the glucose-insulin homeostasis can be provided as the status model.
- the model parameters are, for example, time constants that describe the dynamics of an insulin reaction or a glucose breakdown, or amplifications such as insulin or glucose sensitivities. These model parameters are obviously strongly dependent on the respective patient. Therefore, an update of the model parameters allows an individualization of the model. In this way, it is possible to learn from previous measurements.
- This mechanism is analogous to the second step of the state update described above: in particular, the same cost function ⁇ is used to calculate deviations between model output and measurement. But now the gradient jik is determined with regard to the model parameter 0k. This gradient is used with a separate gradient method to correct the model parameters.
- the algorithm is shown in Figures 4 and 5 in detail.
- the current statuses Xk provide the patient with current information about their metabolic (diabetic) health status. This information is more comprehensive than just the blood glucose reading.
- predictions can be made to support therapy planning (cf. FIG. 2). For example, based on the current status, the course of the blood glucose can be predicted over the next 120 minutes.
- the individualized model parameters 0k allow a better tailored depiction of the patient in the model of the glucose-insulin homeostasis in the sense of a "digital twin".
- the model parameters obtained can be used for diagnosis (cf. FIG. 2).
- a decreasing insulin sensitivity can e.g. B. indicate a worsening of the diabetic disease.
- the automatic differentiation method (using dual numbers) is used to calculate the two gradients (cf. e.g. RD Neidinger, Introduction to Automatic Differentiation and MATLAB Object-Oriented Programming, SIAM Rev. 52 (2010) 545-563; and Maclaurin D, Duvenaud D, Matt Johnson M, Townsend J, autograd: Software package that automatically differentiate native Python and Numpy code, 2020). This means that no analytical or symbolic derivations need to be determined.
- the method offers an exact solution and is therefore also advantageous compared to approximation methods such as calculation using difference quotients.
- the state vector x and the input vector u are taken as Are defined. This allows the differential equations from the table above to be summarized for the state differential equation: The model parameters to be identified are separated and form the parameter vector 0.
- State estimation can be realized by Bayesian estimators (e.g. Kalman filters), but this requires additional effort. Especially for non-linear systems, special solutions have to be found, while the parallel estimation is also directly suitable for non-linear systems and can be carried out from one approach.
- Bayesian estimators e.g. Kalman filters
- model-based regulation model predictive control, MPC
- MPC model predictive control
- Diabetes Companion Provides a more comprehensive diagnosis of your current condition compared to just reading your glucose reading. Feedback of the current status to the patient, any alarms.
- Predictions can be made from the current status and scenarios (e.g. for different meals) can be carried out. Such simulations can also support patient education.
- Health status tracking The model parameters of the individual model can be used to estimate the health status. This is done retrospectively, trends can be derived.
- FIG. 6 shows a method according to the invention for determining a patient's state of health.
- the method comprises the steps of receiving S10 a measured glucose value and an input glucose uptake value, determining S12 the state of health of the Patients, determining S14 a deviation and the patient-specific update S16 of a model parameter.
- the method can be implemented, for example, in the form of an app that can be run on a mobile device, in particular a smartphone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Physiology (AREA)
- Artificial Intelligence (AREA)
- Signal Processing (AREA)
- Emergency Medicine (AREA)
- Optics & Photonics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE112022006079.4T DE112022006079A5 (de) | 2021-12-22 | 2022-09-28 | Verfahren, vorrichtung und system zum ermitteln eines gesundheitszustands eines patienten |
EP22793167.2A EP4452063A1 (de) | 2021-12-22 | 2022-09-28 | Verfahren, vorrichtung und system zum ermitteln eines gesundheitszustands eines patienten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102021134292 | 2021-12-22 | ||
DE102021134292.9 | 2021-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023117164A1 true WO2023117164A1 (de) | 2023-06-29 |
Family
ID=83902716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/076936 WO2023117164A1 (de) | 2021-12-22 | 2022-09-28 | Verfahren, vorrichtung und system zum ermitteln eines gesundheitszustands eines patienten |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4452063A1 (de) |
DE (1) | DE112022006079A5 (de) |
WO (1) | WO2023117164A1 (de) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100262117A1 (en) * | 2007-11-02 | 2010-10-14 | University Of Virginia Patent Foundation | Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing |
US20150190098A1 (en) * | 2011-08-26 | 2015-07-09 | Stephen D. Patek | Method, System and Computer Readable Medium for Adaptive and Advisory Control of Diabetes |
US20200197605A1 (en) * | 2017-05-05 | 2020-06-25 | Eli Lilly And Company | Closed loop control of physiological glucose |
-
2022
- 2022-09-28 WO PCT/EP2022/076936 patent/WO2023117164A1/de active Application Filing
- 2022-09-28 EP EP22793167.2A patent/EP4452063A1/de active Pending
- 2022-09-28 DE DE112022006079.4T patent/DE112022006079A5/de active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100262117A1 (en) * | 2007-11-02 | 2010-10-14 | University Of Virginia Patent Foundation | Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing |
US20150190098A1 (en) * | 2011-08-26 | 2015-07-09 | Stephen D. Patek | Method, System and Computer Readable Medium for Adaptive and Advisory Control of Diabetes |
US20200197605A1 (en) * | 2017-05-05 | 2020-06-25 | Eli Lilly And Company | Closed loop control of physiological glucose |
Non-Patent Citations (6)
Title |
---|
C. COBELLIC.D. MANG. SPARACINOL. MAGNI, G. DE NICOLAOB.P. KOVATCHEV: "Diabetes: Models, Signals, and Control", IEEE REV. BIOMED. ENG., vol. 2, 2009, pages 54 - 96 |
C. DALLA MANR.A. RIZZAC. COBELLI: "Meal simulation model of the glucose-insulin system", IEEE TRANS. BIOMED. ENG., vol. 54, 2007, pages 1740 - 1749 |
D. MACLAURIND. DUVENAUDM. MATT JOHNSONJ. TOWNSEND, SOFTWARE PACKAGE THAT AUTOMATICALLY DIFFERENTIATE NATIVE PYTHON AND NUMPY CODE, 2020 |
EBERLE ET AL., REAL-TIME STATE ESTIMATION AND LONG-TERM MODEL ADAPTATION: A TWO-SIDED APPROACH TOWARD PERSONALIZED DIAGNOSIS OF GLUCOSE AND INSULIN LEVELS, 2012 |
R.D. NEIDINGER: "Introduction to Automatic Differentiation and MATLAB Object-Oriented Programming", SIAM REV, vol. 52, 2010, pages 545 - 563 |
R.N. BERGMANY.Z. IDERC.R. BOWDENC. COBELLI: "Quantitative estimation of insulin sensitivity", AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, vol. 236, 1979, pages E667 |
Also Published As
Publication number | Publication date |
---|---|
DE112022006079A5 (de) | 2024-10-31 |
EP4452063A1 (de) | 2024-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Heitz | The speed-accuracy tradeoff: history, physiology, methodology, and behavior | |
Kliegel et al. | A process-model based approach to prospective memory impairment in Parkinson's disease | |
Westen | Prototype diagnosis of psychiatric syndromes | |
EP2470913B1 (de) | Kalibrierverfahren zur prospektiven Kalibrierung eines Messgeräts, Computerprogramm und Messgerät | |
EP1589438B1 (de) | Verfahren und Vorrichtung zum Überwachen einer Konzentration eines Analyten im lebenden Körper eines Menschen oder Tieres | |
EP1728469A2 (de) | Bewertung der Glucosekonzentration zur Einstellung der Insulindosierung | |
DE202009003034U1 (de) | Gerät zum Aktivitätsmonitoring | |
DE112020004780T5 (de) | Blutzuckerkontrollsystem | |
WO2022096297A1 (de) | Computerimplementiertes verfahren und vorrichtung zum durchführen einer medizinischen laborwertanalyse | |
EP2409253B1 (de) | Verfahren zum automatischen erzeugen eines nutzerspezifischen messdatenerfassungsregimes für eine diskontinuierliche butzuckermessung sowie datenverarbeitungsvorrichtung und blutzuckermessgerät | |
DE19634577A1 (de) | Verfahren und Anordnung zur Bestimmung individualspezifischer Tagesprofile der Blutzuckerkonzentration, der Insulinwirkung und der Nahrungsresorption | |
EP4452063A1 (de) | Verfahren, vorrichtung und system zum ermitteln eines gesundheitszustands eines patienten | |
Lighthall et al. | Learning and memory in the aging brain: The function of declarative and nondeclarative memory over the lifespan. | |
WO2016202437A1 (de) | Verfahren, computerprogrammprodukt und system zum austausch von gesundheitsdaten | |
WO2012092954A2 (de) | Verfahren zur auswertung eines satzes von messdaten eines oralen glucosetoleranztests | |
EP2236076A1 (de) | Verfahren und System zur Ermittlung der Differenz zwischen prä- und postprandialen Blutzuckerwerten | |
Nguyen et al. | Artificial intelligence and machine learning in diabetes research | |
DE102005028975B4 (de) | Verfahren zur Ermittlung eines Biomarkers zur Kennzeichnung eines spezifischen biologischen Zustands eines Organismus aus mindestens einem Datensatz | |
EP1351181A1 (de) | Computersystem und Verfahren zur Datenerfassung für die Ermittlung des Verlaufs einer chronischen Erkrankung | |
DE102013008594A1 (de) | Verfahren zur datenverarbeitungsgestützten Ermittlung des Kohlenhydratgehalts eines Lebensmittels | |
WO2020104625A1 (de) | Verfahren zur erfassung und bewertung des stoffwechselzustands einer testperson | |
EP1793321A1 (de) | Auswerteverfahren und Untersuchungssystem eines Analyten im Körperflüssigkeit eines Menschen oder Tieres | |
Park et al. | The neurocognitive role of working memory load when Pavlovian motivational control affects instrumental learning | |
DE102017206163A1 (de) | Verfahren und System zur Herstellung von individualisierten Nahrungsmittelmahlzeiten | |
DE102021120512A1 (de) | Bewertungseinheit für ein medizinisches System |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22793167 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 112022006079 Country of ref document: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022793167 Country of ref document: EP Effective date: 20240722 |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: R225 Ref document number: 112022006079 Country of ref document: DE |